Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel

Li, Xiaocheng; Jiang, Zhiyang; Wu, Yafang; Gong, Wei; Liao, Xiaofeng; Li, Yong

doi:10.3389/fonc.2022.935817

Cited by 3 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al found that PD-1 inhibitor combined with S-1 and nab paclitaxel can be used to achieve the transformation treatment of advanced refractory CCA. This combination therapy is safe and effective, and can significantly prolong the survival of patients (54). Previous evidence suggested that PD-1 inhibitors are suitable for patients who have high TMB, high microsatellite instability (MSI-H), deficient mismatch repair (dMMR), and PD-L1 positive expression.…”

Section: Pd-1 and Pd-l1 Inhibitorsmentioning

confidence: 99%

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

et al. 2023

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a highly malignant tumor of the hepatobiliary system that has failed to respond to many traditional therapies to a certain extent, including surgery, chemotherapy and radiotherapy. In recent years, the new therapeutic schemes based on immunology have fundamentally changed the systemic treatment of various malignant tumors to a certain extent. In view of the immunogenicity of CCA, during the occurrence and development of CCA, some immunosuppressive substances are released from cells and immunosuppressive microenvironment is formed to promote the escape immune response of its own cells, thus enhancing the malignancy of the tumor and reducing the sensitivity of the tumor to drugs. Some immunotherapy regimens for cholangiocarcinoma have produced good clinical effects. Immunotherapy has more precise characteristics and less adverse reactions compared with traditional treatment approaches. However, due to the unique immune characteristics of CCA, some patients with CCA may not benefit in the long term or not benefit at all after current immunotherapy. At present, the immunotherapy of CCA that have been clinically studied mainly include molecular therapy and cell therapy. In this article, we generalized and summarized the current status of immunotherapy strategies including molecular therapy and cell therapy in CCA in clinical studies, and we outlined our understanding of how to enhance the clinical application of these immunotherapy strategies.

show abstract

Section: Pd-1 and Pd-l1 Inhibitorsmentioning

confidence: 99%

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

Gimeracil/oteracil/tegafur/paclitaxel

2022

Reactions Weekly

View full text Add to dashboard Cite

PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer

Zhang,

Nie,

Tai

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

Advanced gallbladder cancer (GBC) is not amenable to surgical resection. There are limited treatment options and the prognosis is dismal. The role of immune checkpoint inhibitors in conversion therapy remains unclear for initially unresectable advanced GBC. We present a case of a woman in her late 60s diagnosed with stage IV GBC with liver and para-aortic and retroperitoneal lymph node metastases, who achieved a pathological complete response after three cycles of programmed cell death-ligand 1 inhibitor durvalumab combined with gemcitabine and cisplatin regimen and underwent conversion surgery without complication. The patient went on to develop disease progression without adjuvant therapy 6 months after surgery.

show abstract

Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel

Cited by 3 publications

References 46 publications

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Gimeracil/oteracil/tegafur/paclitaxel

PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer

Contact Info

Product

Resources

About